Automate Your Wheel Strategy on PFE
With Tiblio's Option Bot, you can configure your own wheel strategy including PFE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PFE
- Rev/Share 11.0067
- Book/Share 15.9713
- PB 1.5001
- Debt/Equity 0.6785
- CurrentRatio 1.2581
- ROIC 0.0897
- MktCap 135766635600.0
- FreeCF/Share 1.665
- PFCF 14.3684
- PE 17.2285
- Debt/Assets 0.2946
- DivYield 0.0712
- ROE 0.0878
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | PFE | Cantor Fitzgerald | -- | Neutral | -- | $24 | April 22, 2025 |
| Resumed | PFE | BofA Securities | -- | Neutral | -- | $29 | Dec. 10, 2024 |
| Initiation | PFE | Bernstein | -- | Market Perform | -- | $32 | Oct. 17, 2024 |
News
Pfizer Boasts Strong Oncology Portfolio: Can it Sustain Growth?
Published: June 19, 2025 by: Zacks Investment Research
Sentiment: Neutral
PFE's oncology portfolio, boosted by Seagen and late-stage pipeline assets, may fuel growth amid lackluster stock performance.
Read More
RFK Jr weighs review of vaccines citing aluminum use, Bloomberg News reports
Published: June 18, 2025 by: Reuters
Sentiment: Neutral
U.S. Health Secretary Robert F. Kennedy Jr. is considering asking a key government vaccine advisory panel to examine vaccines that contain aluminum ingredients, Bloomberg News reported on Wednesday, citing a source familiar with the matter.
Read More
RFK Jr.'s new vaccine advisors will vote on flu shots containing mercury
Published: June 18, 2025 by: CNBC
Sentiment: Neutral
A revamped government panel of vaccine advisors appointed by Health and Human Services Secretary Robert F. Kennedy Jr. will soon vote on a shot preservative that contains mercury, which is safely used in some flu jabs but has been incorrectly linked to autism in the past.
Read More
3 High-Yield Dividend Stocks Increasing Payouts For Decades
Published: June 18, 2025 by: 24/7 Wall Street
Sentiment: Positive
These dividend stocks have high yields and solid upside potential. They also have quality underlying businesses.
Read More
Should Value Investors Buy Pfizer (PFE) Stock?
Published: June 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
5 Low Price-to-Book Value Stocks That You Can Buy in June
Published: June 17, 2025 by: Zacks Investment Research
Sentiment: Positive
The P/B ratio helps to identify low-priced stocks with high growth prospects. USNA, CVS, PFE, STNE and PSFE are some such stocks.
Read More
PFE or LLY: Which Is the Better Value Stock Right Now?
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and Eli Lilly (LLY). But which of these two stocks is more attractive to value investors?
Read More
4 Value Stocks to Shield Your Portfolio Amid Geopolitical Turmoil
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Positive
As geopolitical risks jolt markets, STNE, CNC, CVS and PFE shine with low cash flow valuations and solid earnings outlooks.
Read More
5 Large Drug Stocks That Are Poised to Ride on Sector Recovery
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Neutral
In the Large-Cap Pharmaceuticals industry, AbbVie, Novartis, Pfizer, Sanofi and Bayer are worth retaining amid macro pressure and rising innovation.
Read More
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (NYSE: PFE)
Published: June 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
PHILADELPHIA, June 12, 2025 (GLOBE NEWSWIRE) -- Berger Montague advises shareholders of Pfizer Inc. (“Pfizer” or the “Company”) (NYSE: PFE) about an investigation into Pfizer's Board of Directors for potential breaches of fiduciary duties to Pfizer and its shareholders in connection with the Company's marketing and sale of Depo-Provera.
Read More
PFE's New & Acquired Drugs Hold Key to Revenue Growth Amid Headwinds
Published: June 12, 2025 by: Zacks Investment Research
Sentiment: Neutral
PFE's new drug launches and Seagen acquisition are driving revenue gains despite COVID declines and market headwinds.
Read More
4 Cheap Dividend Stocks Under $50 That Keep Raising Payouts
Published: June 12, 2025 by: 24/7 Wall Street
Sentiment: Positive
These four dividend stocks are trading below $50 and have a yield higher than 4%.
Read More
4 Battered Blue Chips Trading at Multiyear Lows Pay Huge High-Yield Dividends
Published: June 10, 2025 by: 24/7 Wall Street
Sentiment: Neutral
Blue-chip stocks are shares of large, well-established, financially stable companies with a consistent and reliable performance history.
Read More
5 Ideal 'Safe' Buys From June Fortune Return On Leadership Screen
Published: June 10, 2025 by: Seeking Alpha
Sentiment: Positive
Coincident to the June 5, 2025 annual launch of their Fortune 500, Fortune also partnered with Indiggo to measure Return On Leadership, called the ROL100. Arnold research focused on those 100 using YCharts 6/6/25 data on Dividends from 78, which hereafter are referred to as the Fortune Return on Leadership Dividend Dogs (FROLD). ReturnOnLeadership is based on four fundamental factors: Connection to Purpose, Strategic Clarity, Leadership Alignment, and Focused Action.
Read More
Top Cancer Stocks to Supercharge Your 2025 Portfolio
Published: June 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer, Novartis and Fate Therapeutics are making bold oncology moves as demand surges for next-gen cancer therapies.
Read More
Vaccine stocks muted as Wall Street takes 'wait and watch' approach after Kennedy's shake-up
Published: June 10, 2025 by: Reuters
Sentiment: Neutral
Shares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach after U.S. Health Secretary Robert F. Kennedy Jr. fired all members of an expert vaccine panel late on Monday.
Read More
Wall Street Analysts Love These Ultra-High Yield Dividend Stocks
Published: June 10, 2025 by: 24/7 Wall Street
Sentiment: Positive
Alexandros Michailidis / iStock Editorial via Getty Images Pfizer Pharmaceutical company Pfizer Inc.
Read More
Pfizer Stock Down Almost 11% YTD: Should You Buy the Dip?
Published: June 09, 2025 by: Zacks Investment Research
Sentiment: Negative
PFE lags the market as COVID sales drop and patent losses loom, but new drugs and cost cuts may fuel a comeback.
Read More
Pfizer Inc. (PFE) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Published: June 09, 2025 by: Seeking Alpha
Sentiment: Neutral
Pfizer Inc. (NYSE:PFE ) Goldman Sachs 46th Annual Global Healthcare Conference June 9, 2025 8:00 AM ET Company Participants Albert Bourla - Chairman of the Board & CEO Conference Call Participants Asad Haider - Goldman Sachs Group, Inc., Research Division Asad Haider Great. Good morning, everyone, and welcome to our 46th Annual Global Healthcare Conference.
Read More
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Published: June 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Published: June 09, 2025 by: Benzinga
Sentiment: Positive
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Read More
Buy 7 Ideal 'Safer' May Dividends, Out Of 40 Reader Tags
Published: June 06, 2025 by: Seeking Alpha
Sentiment: Positive
My yield-based 'dogcatcher' strategy spotlights high-yield stocks whose dividends from $1,000 invested exceed their share price, favoring underdogs for income growth. Analyst targets project average net gains of 41.9% for the top ten May 2025 ReFa/Ro Dogs, with Oxford Lane Capital leading at 83.4% upside potential. All ten top ReFa/Ro Dogs currently meet my 'ideal' criteria, but caution is warranted as several have negative free cash flow margins, signaling cash-poor status.
Read More
5 Bargain Stocks With Low P/S Ratios & High Growth Return Potential
Published: June 05, 2025 by: Zacks Investment Research
Sentiment: Positive
The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like JAKK, GDOT, SIG, ROCK and PFE hold promise.
Read More
Here Are All 6 Stocks I've Bought Through 5 Months of 2025
Published: June 05, 2025 by: The Motley Fool
Sentiment: Positive
It's been a wild ride for the stock market through the first five months of 2025. As of mid-February, Wall Street's major stock indexes could do no wrong, with the benchmark S&P 500 vaulting to an all-time record-closing high.
Read More
Top 3 dividend stocks to buy for 2026
Published: June 04, 2025 by: Finbold
Sentiment: Positive
Holding dividend stocks remains one of the most effective long-term strategies, with companies that pay a regular dividend often being profitable and well-positioned for future growth, even during economic downturns.
Read More
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (June 2025)
Published: June 04, 2025 by: 24/7 Wall Street
Sentiment: Positive
Jeff J Mitchell / Getty Images News via Getty Images Pfizer (PFE) Price Prediction 2025–2030 The current consensus one-year price target for Pfizer, according to analysts, is $27.63, which represents 17.42% potential upside over the next 12 months based on PFE's current share price.
Read More
Pfizer's R&D Optimization Delivers Great Results & Secure Dividends
Published: June 03, 2025 by: Seeking Alpha
Sentiment: Positive
PFE's meltdown has already triggered the richer forward dividend yields, made secure by the growing cash flow and the ongoing cost optimizations. The same has been observed in the FQ1'25 adj EPS outperformance, reiterated FY2025 guidance, and them "currently trending toward the upper end of the adjusted diluted EPS guidance range." While there is no avoiding the COVID-19 sales erosion and the upcoming patent cliff with ~$29B in revenues at stake, PFE has optimized its R&D efforts indeed.
Read More
Top 4 Value Stocks to Buy as Trade Tensions Still Cloud H2 Outlook
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
STNE, CNC, CVS and PFE stand out as top value picks amid trade tensions and a murky H2 economic outlook.
Read More
Buy, Sell, Or Hold PFE Stock At $23?
Published: June 03, 2025 by: Forbes
Sentiment: Negative
Pfizer (NYSE:PFE) stock is down around 25% from its 52-week high of over $31 to $23 now. Pipeline setbacks, including an experimental treatment for Duchenne muscular dystrophy (DMD) failing in a late-stage trial, and concerns about management's decisions on R&D spending and acquisitions have weighed on Pfizer's stock lately.
Read More
3 Low-Priced Dividend Stocks Paying Over 5% Right Now
Published: June 03, 2025 by: 24/7 Wall Street
Sentiment: Positive
Alexandros Michailidis / iStock Editorial via Getty Images Pfizer The years after the pandemic haven't been kind to Pfizer Inc.
Read More
About Pfizer Inc. (PFE)
- IPO Date 1972-06-01
- Website https://www.pfizer.com
- Industry Drug Manufacturers - General
- CEO Dr. Albert Bourla D.V.M., Ph.D.
- Employees 81000